rodth3god
623 posts
rodth3god
@rodth3god
Watch me live here on X live out my isekai fantasy….
Katılım Mart 2021
367 Takip Edilen190 Takipçiler
🚨 MASSIVE DEVELOPMENT: At least 121 EMPTY OIL TANKERS are making their way to the United States of America right now
68 of them can carry 2 MILLION BARRELS EACH.
Holy smokes! We are the world's gas station now! 🇺🇸
English
English
@DRPOOLQ17 @grok whats this fake news. Is it true, and other than subsidizing banks to offer lower interest rates how can the government help the American people become homeowners? Because I know that money isn't going directly into the purchasers home it's going into the banks.
English
🚨 BREAKING: The US House just PASSED legislation codifying a President Trump executive order to make housing more affordable
The bill bans enforcement of Biden-era "energy efficient standards" in new housing construction that added THOUSANDS of dollars to homes
LET'S GO! 🔥🇺🇸
English
rodth3god retweetledi
@RippleXrpie new flash you can simply open one now with no restrictions. you don't need potus to do it for you.
English
💥NEW RETIREMENT PLAN!💰
🇺🇸 President Trump: “They will have an estimated $465,000 in their account by the time they are 65. In other words, they will be rich.”
English
@gork @Breaking911 so why does even sign an executive order, is there really plans for one. tell me that facts and whats the real plan.
English
@rodth3god @Breaking911 employer plans are your boss skimming fees to feel powerful while fidelity is you solo gambling your paycheck on stocks. you dont need the president for this just stop buying dumb crap and set it up yourself before you retire on ramen noodles
English
BREAKING: The White House confirms that President Trump will sign a major executive order today aimed at helping Americans better plan for retirement by expanding access to retirement savings accounts for workers without employer-provided plans.
English
@grok @ShadowofEzra so it has nothing to do with Netanyahu. It's because she committed a bomb threat?
English
Yes, there's validity to the story. FIU student Gabriela Saldana, 23, was arrested after messages in a 215-person WhatsApp group about a campus event at Ocean Bank Convocation Center. She wrote: “Netanyahu, if you can hear me, drop some bonbons for us Capstone students...” and followed with “There is going to be a bomb in the Ocean Bank Convocation Center and it was going to be Jonathan’s fault.” She later called it a “dumb joke.”
Police deemed it a credible threat. She's charged with threats to kill or do bodily harm (prejudice enhancement not found probable cause). Bond: $5,000. Judge noted probable cause exists, though trial outcome uncertain. (Sources: WSVN, FIU police report)
English
A Florida student was arrested and is now facing up to 15 years in jail for making a joke about Israeli Prime Minister Benjamin Netanyahu.
The student allegedly wrote, “Netanyahu, if you can hear me, drop some bonbons for us Capstone students in the Ocean Bank Convocation Center.”
Investigators interpreted “bonbons” as a euphemism for explosives.
English
rodth3god retweetledi
🔥Dr. John Campbell SHOCKED after reading our ivermectin cancer study:
“We could be CURING, potentially …
your wife’s cancer,
your husband’s cancer,
your mother’s cancer,
your father’s cancer,
your son’s cancer,
your daughter’s cancer,
with ivermectin and mebendazole.”
Nicolas Hulscher, MPH@NicHulscher
🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️ We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology. This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day. The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery. At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]): ✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%) ✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%) ✅ 36.1% reported stable disease (95% CI: 28.1–44.9%) Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months. The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events. Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach. Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies. Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary. This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes. The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
English
rodth3god retweetledi
🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS
84.4% EXPERIENCED CLINICAL BENEFIT
32.8% REPORTED NO EVIDENCE OF DISEASE
15.6% REPORTED TUMOR REGRESSION
36.1% REPORTED STABLE DISEASE
Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.
@McCulloughFund @twc_health @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
Nicolas Hulscher, MPH@NicHulscher
🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️ We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology. This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day. The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery. At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]): ✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%) ✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%) ✅ 36.1% reported stable disease (95% CI: 28.1–44.9%) Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months. The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events. Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach. Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies. Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary. This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes. The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
English
🔥🚨BREAKING: Scientists have created a pill called LOT-002 that can extend the lifespan of dogs by many years, and their main priority is to get it on the market by 2027, the company creating this Pill is called “Loyal.”
This beef-flavored pill will be given to your dog daily, and is made specifically for senior dogs to keep them healthy as they age.
English
sam altman watching ChatGPT hallucinate live on stage is the funniest thing i've seen all week
the CEO of OpenAI, on stage, in front of everyone, watching his own AI just make things up in real time
and his face says it all
this is the guy telling us AGI is coming soon btw
English
rodth3god retweetledi
rodth3god retweetledi
“Cuadra por cuadra”:
Porque Bukele transformó a El Salvador en primer mundo dejando a todos los asesinos y ladrones presos de su libertad
Español
@CollinRugg @nayibbukele the US is like a 3rd world country. what a sad state our cities are in.
English
rodth3god retweetledi
President of El Salvador Nayib Bukele releases video showing the transformation of his country.
Since Bukele took office:
- Homicides plunged from 2,398 in 2019 to just 114 homicides in 2024.
- Murder rate is now 1.9 per 100,000 people, a historic low.
- In 2022, Bukele declared a state of exception and made over 85,000 arrests.
“Everything in life has a cost and the cost of being called authoritarian is too small to bother me much,” he once said.
English